Rubedo Life Science CEO Frederick Beddingfield III, MD, PhD, FAAD, FACMS, talks about the importance of addressing aging and senescence, and his company's investigational drug that targets pathological senescent cells and surrounding tissues that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process.
advertisement
Targeting Senescent Cells
Share
SaveShare this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Recommended
Details
Overview
Rubedo Life Science CEO Frederick Beddingfield III, MD, PhD, FAAD, FACMS, talks about the importance of addressing aging and senescence, and his company's investigational drug that targets pathological senescent cells and surrounding tissues that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?